MCID: FLR002
MIFTS: 55

Filariasis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Filariasis

MalaCards integrated aliases for Filariasis:

Name: Filariasis 12 74 58 54 15 71 32
Disease Due to Superfamily Filarioidea 12

Characteristics:

Orphanet epidemiological data:

58
filariasis
Inheritance: Not applicable; Prevalence: >1/1000; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1080
ICD9CM 34 125.9
NCIt 49 C34611
SNOMED-CT 67 105706003
MESH via Orphanet 44 D005368
ICD10 via Orphanet 33 B74.0 B74.1 B74.2 more
UMLS via Orphanet 72 C0016085
Orphanet 58 ORPHA2034
UMLS 71 C0016085

Summaries for Filariasis

Disease Ontology : 12 A parasitic helminthiasis infectious disease that involves parasitic infection of the lymphatics and subcutaneous tissue by nematodes of the superfamily Filarioidea.

MalaCards based summary : Filariasis, also known as disease due to superfamily filarioidea, is related to filarial elephantiasis and onchocerciasis. An important gene associated with Filariasis is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Diethylcarbamazine and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include testes, breast and skin, and related phenotypes are immune system and digestive/alimentary

Wikipedia : 74 Filariasis is a parasitic disease caused by an infection with roundworms of the Filarioidea type. These... more...

Related Diseases for Filariasis

Diseases related to Filariasis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 826, show less)
# Related Disease Score Top Affiliating Genes
1 filarial elephantiasis 34.8 TLR4 TLR2 IL5 IL10
2 onchocerciasis 32.7 LGALS3BP IL5 IL2 IGHE CCL5
3 volvulus of midgut 31.7 TLR2 CRP ALB
4 lymphangitis 31.5 FLT4 CRP ALB
5 eosinophilic pneumonia 31.4 IL6 IL5 CCL5
6 hypereosinophilic syndrome 31.2 IL5 IL2 IL10 IGHE IFNG CCL5
7 endomyocardial fibrosis 31.1 TNF IL5 IL10
8 ascaris lumbricoides infection 31.0 IL6 IL5 IL10 IFNG
9 lymphadenitis 31.0 TNF TLR4 IL10 IFNG CRP
10 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.0 IL10 IFNG CTLA4
11 strongyloidiasis 30.8 LGALS3BP IL5 IGHE IFNG
12 encephalitis 30.8 TNF TLR2 IL6 IL10 CCL5
13 orchitis 30.7 TNF IL6 IL2 IL10 CRP
14 cysticercosis 30.7 TLR4 IL6 IL10 IGHE
15 parasitic helminthiasis infectious disease 30.7 TNF TLR4 TLR2 IL6 IL5 IL2
16 trachoma 30.6 TNF IL6 IL10
17 yellow fever 30.6 IL6 IL5 CRP CCL5
18 chikungunya 30.6 TNF IL6 CCL5
19 toxocariasis 30.6 IL5 IL10 IGHE CRP
20 poliomyelitis 30.6 TNF IL10 IFNG
21 lymphangioma 30.6 IL6 IFNG FLT4
22 taeniasis 30.6 TNF TLR4 IL10 ALB
23 severe combined immunodeficiency 30.6 IL6 IL5 IL2 IL10 IFNG
24 trichomoniasis 30.5 TNF IL6 IL2
25 ige responsiveness, atopic 30.4 IL5 IL10 IGHE IFNG
26 pericardial effusion 30.4 IL6 CRP ALB
27 mastitis 30.4 TLR2 IL6 CCL5 ALB
28 fascioliasis 30.4 IL10 IFNG ALB
29 amebiasis 30.3 TNF TLR4 TLR2 ALB
30 rheumatic heart disease 30.3 TNF TLR2 IL6 IL10
31 keratitis, hereditary 30.3 TNF TLR4 TLR2 IL6
32 schistosomiasis 30.3 TNF IL5 IL2 IL10 IGHE IFNG
33 protein-energy malnutrition 30.3 TNF IL6 ALB
34 tracheitis 30.3 TNF IL6 CRP
35 arthropathy 30.3 TNF IL6 IFNG CRP
36 tenosynovitis 30.3 TNF IL6 CRP
37 iritis 30.3 TNF IL6 CRP
38 urinary schistosomiasis 30.3 IL5 IL10 IGHE IFNG CTLA4
39 systemic autoimmune disease 30.3 IL6 CRP
40 pulmonary hypertension 30.3 TNF IL6 IL10 CRP ALB
41 thrombophlebitis 30.2 TNF CRP ALB
42 b cell deficiency 30.2 TNF IL6 IL2 IL10 CTLA4
43 iridocyclitis 30.2 TNF IL6 IL10 CRP
44 mucocutaneous leishmaniasis 30.2 TNF IL5 IL2 IL10 IFNG
45 amyloidosis 30.2 TNF IL6 CRP ALB
46 panuveitis 30.2 TNF IL6 IL10 CRP
47 lepromatous leprosy 30.2 TNF TLR2 IL2 IL10 IFNG
48 uveitis 30.2 TNF IL6 IL2 IL10 IFNG CTLA4
49 retinal detachment 30.2 TNF IL6 IL10 IFNG
50 necrotizing fasciitis 30.1 IL6 IL2 CRP ALB
51 allergic hypersensitivity disease 30.1 TNF IL5 IL2 IL10 IGHE IFNG
52 posterior uveitis 30.1 TNF IL6 IL5 IL2 IFNG
53 cystic echinococcosis 30.1 TLR4 TLR2 IL6 IL10 IGHE IFNG
54 pericarditis 30.1 TNF IL6 IFNG CRP ALB
55 varicose veins 30.1 TNF LGALS3BP IL6 FOXC2
56 gastritis 30.1 TNF TLR4 IL6 IL10 CCL5
57 vasculitis 30.0 TNF IL6 IL10 CTLA4 CRP
58 end stage renal disease 30.0 TNF IL6 CRP ALB
59 echinococcosis 30.0 TNF TLR4 TLR2 IL6 IL5 IL10
60 disease of mental health 30.0 TNF IL6 CRP ALB
61 epidemic typhus 30.0 TLR4 TLR2 IL10 CRP CCL5
62 urticaria 30.0 TNF IL6 IL5 IL10 IGHE CRP
63 pancytopenia 29.9 IL6 IFNG CRP ALB
64 pulmonary edema 29.9 TNF IL10 CRP
65 typhoid fever 29.9 TNF TLR4 IL6 IFNG CRP ALB
66 fasciitis 29.9 TNF IL6 IL2 IFNG CRP
67 endocarditis 29.9 TNF TLR6 TLR2 IL6 IL10 IFNG
68 bacterial infectious disease 29.9 TNF TLR9 TLR4 TLR2 TLR1 IL6
69 syphilis 29.9 TNF IL6 IFNG CRP ALB
70 scrub typhus 29.8 TNF TLR4 TLR2 IL10 IFNG CRP
71 pleurisy 29.8 TNF TLR4 TLR2 IL2 IFNG CRP
72 dengue hemorrhagic fever 29.8 TNF TLR9 IL6 IL10 IFNG ALB
73 diarrhea 29.8 TNF TLR4 IL6 IL5 IL2 IL10
74 cellulitis 29.7 TNF IL6 IL5 IL2 IL10 IFNG
75 hepatitis b 29.7 TNF TLR4 TLR2 IL6 IFNG CTLA4
76 leprosy 3 29.7 TNF TLR9 TLR6 TLR4 TLR2 TLR1
77 meningoencephalitis 29.7 TNF IL6 IL10 CRP CCL5 ALB
78 lichen planus 29.7 TNF TLR2 IL6 IL2 IL10 IFNG
79 tetanus 29.6 TNF IL6 IL5 IL2 IL10 IFNG
80 immune deficiency disease 29.6 TNF TLR9 TLR2 IL6 IL2 IL10
81 dermatitis 29.6 TNF TLR9 IL6 IL5 IL2 IL10
82 leishmaniasis 29.6 TNF TLR9 TLR4 TLR2 IL6 IL5
83 keratoconjunctivitis 29.6 TNF IL6 IL5 IL2 IFNG CCL5
84 plague 29.5 TNF TLR9 TLR6 TLR4 TLR2 TLR1
85 acquired immunodeficiency syndrome 29.5 TNF IL6 IL2 IL10 IFNG CRP
86 plasmodium falciparum malaria 29.5 TNF IL6 IL10 IFNG CRP CHIT1
87 trypanosomiasis 29.5 TNF TLR9 TLR6 TLR4 TLR2 IL6
88 pulmonary tuberculosis 29.5 TNF TLR4 TLR2 IL6 IL2 IL10
89 visceral leishmaniasis 29.5 TNF TLR9 TLR4 TLR2 IL2 IL10
90 cutaneous leishmaniasis 29.4 TNF TLR9 TLR4 TLR2 IL6 IL5
91 skin disease 29.4 TNF TLR2 IL6 IL5 IL2 IL10
92 exanthem 29.4 TNF IL6 IL2 IL10 IFNG CTLA4
93 vascular disease 29.4 TNF TLR4 IL6 IL2 IL10 IFNG
94 mycobacterium tuberculosis 1 29.4 TNF TLR9 TLR4 TLR2 TLR1 IL10
95 toxoplasmosis 29.4 TNF TLR9 TLR4 TLR2 TLR1 IL6
96 chagas disease 29.3 TNF TLR9 TLR6 TLR4 TLR2 IL6
97 arthritis 29.3 TNF TLR4 TLR2 IL6 IL10 IFNG
98 bronchitis 29.1 TNF TLR4 TLR2 IL6 IL5 IL10
99 peritonitis 29.1 TNF TLR4 TLR2 IL6 IL10 IFNG
100 psoriasis 29.1 TNF TLR9 TLR2 IL6 IL5 IL2
101 lung disease 28.9 TNF TLR9 TLR4 TLR2 IL6 IL5
102 autoimmune disease 28.9 TNF TLR9 IL6 IL5 IL2 IL10
103 malaria 28.8 TNF TLR9 TLR6 TLR4 TLR2 TLR1
104 proteasome-associated autoinflammatory syndrome 1 28.7 TNF TLR9 TLR6 TLR4 TLR2 IL6
105 dermatitis, atopic 28.6 TNF TLR9 TLR4 TLR2 IL6 IL5
106 parasitic protozoa infectious disease 28.6 TNF TLR9 TLR6 TLR4 TLR2 TLR1
107 systemic lupus erythematosus 28.4 TNF TLR9 TLR4 TLR2 IL6 IL5
108 asthma 27.7 TNF TLR9 TLR6 TLR4 TLR2 TLR1
109 loiasis 12.3
110 elephantiasis 11.8
111 dirofilariasis 11.8
112 mansonelliasis 11.8
113 podoconiosis 11.5
114 dipetalonemiasis 11.5
115 setariasis 11.2
116 hydrocele 10.9
117 hereditary lymphedema i 10.8
118 punctate inner choroidopathy 10.7 TNF IL10
119 aztreonam allergy 10.6 IL5 IL2
120 tropical endomyocardial fibrosis 10.6 TNF IL10
121 external pathological resorption 10.6 TNF IL6
122 tularemia 10.6 TNF TLR4 TLR2
123 silo filler's disease 10.6 TLR4 TLR2 IL5
124 multifocal choroiditis 10.6 TNF IL10
125 eosinophilic fasciitis 10.6 IL5 IFNG
126 microscopic polyangiitis 10.6 TNF CTLA4
127 spondylarthropathy 10.6 TNF TLR4 TLR2
128 myelitis 10.6 TNF IL6 IL10
129 eosinophilic meningitis 10.6 IL5 IL2 IL10
130 metal allergy 10.6 TNF TLR4 IL10
131 acute transverse myelitis 10.6 IL6 IL10
132 idiopathic anterior uveitis 10.6 TNF IL6
133 skin sarcoidosis 10.6 TNF IL2 CTLA4
134 palladium allergic contact dermatitis 10.6 TNF IL10
135 angioimmunoblastic lymphadenopathy with dysproteinemia 10.6 TNF IL6 IL5
136 alveolar echinococcosis 10.6 TNF TLR4 TLR2
137 cow milk allergy 10.6 TNF IL5 IL10
138 toxic pneumonitis 10.6 TLR6 TLR4
139 schistosoma mansoni infection, susceptibility/ 10.6
140 streptococcal toxic-shock syndrome 10.6 TNF IL6 IL2
141 cefaclor allergy 10.6 IL5 ALB
142 meningococcal meningitis 10.5 TLR9 TLR4 TLR2
143 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.5 IL2 IL10 CTLA4
144 post-transplant lymphoproliferative disease 10.5 TNF IL6 IL10
145 fixed drug eruption 10.5 IL2 IFNG
146 transverse myelitis 10.5 TNF IL6 IL10
147 chemical colitis 10.5 TNF IL6 IL10
148 fungal keratitis 10.5 TLR4 TLR2
149 nickel allergic contact dermatitis 10.5 IL5 IL10 IFNG
150 periapical periodontitis 10.5 TNF TLR2 IL6
151 sympathetic ophthalmia 10.5 TNF IL10 CTLA4
152 progressive myoclonus epilepsy 8 10.5 TNF IL6 IL10
153 mycobacterium abscessus 10.5 TNF TLR2 TLR1
154 autoimmune myocarditis 10.5 TNF IFNG
155 dermatitis herpetiformis 10.5 TNF IL5 IL10
156 drug reaction with eosinophilia and systemic symptoms 10.5 TNF CRP
157 burning mouth syndrome 10.5 TNF IL6 IL2
158 poems syndrome 10.5 TNF IL6 IL2
159 pulmonary eosinophilia 10.5
160 capillary disease 10.5 IL2 FLT4 ALB
161 polyarticular juvenile idiopathic arthritis 10.5 TNF IFNG
162 pulpitis 10.5 TNF TLR4 IL6
163 pneumonic plague 10.5 TNF TLR4 TLR2 IL10
164 haemophilus influenzae 10.5 TNF TLR2
165 tick-borne encephalitis 10.5 TLR2 IL10 ALB
166 chronic graft versus host disease 10.5 IL10 IFNG ALB
167 egg allergy 10.5 IL5 IL10 IGHE
168 lacrimal apparatus disease 10.5 TNF IL6 IL10
169 respiratory syncytial virus infectious disease 10.5 IL5 CCL5
170 cardiac sarcoidosis 10.5 TNF IL5 IFNG
171 chronic duodenal ileus 10.5 CRP ALB
172 choroiditis 10.5 TNF IL10 IFNG
173 macs syndrome 10.5 TNF IL10 IFNG
174 b-cell growth factor 10.5 IL6 IFNG
175 mikulicz disease 10.5 IL5 IL10 CRP
176 capillary leak syndrome 10.5 IL6 IL2 ALB
177 blau syndrome 10.5 TNF TLR4 TLR2 IL10
178 peptic esophagitis 10.5 TNF IL6 ALB
179 eclampsia 10.5 TNF IL6 ALB
180 periodic fever, familial, autosomal dominant 10.5 TNF TLR4 IL6
181 silicosis 10.5 TNF TLR4 IL10
182 cardiomyopathy, familial hypertrophic, 20 10.5 TNF IL6 ALB
183 suppurative otitis media 10.5 TLR4 TLR2 CRP
184 churg-strauss syndrome 10.5 TNF IL5 IL2 IL10
185 cytomegalovirus retinitis 10.5 TNF IL10 IFNG
186 yemenite deaf-blind hypopigmentation syndrome 10.5
187 cold agglutinin disease 10.5 IL6 CRP
188 neonatal jaundice 10.5 TNF IL6 IL10
189 obesity-hypoventilation syndrome 10.5 IL6 CCL5
190 crimean-congo hemorrhagic fever 10.5 TNF IL6 CHIT1
191 pneumonic tularemia 10.5 TNF TLR4 TLR2 IL6
192 mycetoma 10.5 IL10 CHIT1 CCL5
193 farmer's lung 10.5 TNF IL2 IGHE
194 wells syndrome 10.5 IL5 IL2 CRP
195 dental pulp disease 10.5 TNF TLR4 TLR2 IL6
196 periapical granuloma 10.5 TLR2 IL2 CCL5
197 macular retinal edema 10.5 TNF IL6 ALB
198 crohn's colitis 10.5 TNF IL2 IFNG
199 status asthmaticus 10.5 IL5 IL10 CCL5
200 scorpion envenomation 10.5 TNF IL6 CCL5
201 hidradenitis suppurativa 10.5 TNF TLR4 IFNG
202 cryptococcosis 10.5 TNF IL10 IFNG
203 acute kidney tubular necrosis 10.5 TNF IL6 ALB
204 hidradenitis 10.5 TNF TLR4 IFNG
205 genital herpes 10.5 TLR2 IL10 CCL5
206 latex allergy 10.5 TNF IL5 IGHE
207 uremic pruritus 10.5 IL6 IL2 CRP
208 leukemia, acute monocytic 10.5 TNF TLR4 TLR2 IL6
209 molluscum contagiosum 10.5 TNF TLR9 TLR2
210 inflammatory bowel disease 1 10.5 TNF TLR4 TLR2 IL6
211 tuberculoid leprosy 10.5 TLR2 IL2 IL10 IFNG
212 salpingitis 10.5 TNF TLR2 CRP
213 pulmonary alveolar proteinosis 10.5 TNF IL6 IL10
214 legionnaire disease 10.5 TLR4 TLR2 CRP
215 toxic oil syndrome 10.5 IL5 IGHE IFNG
216 toxicodendron dermatitis 10.5 TNF IL2
217 prostatitis 10.5 TNF IL6 IL10
218 hypersplenism 10.5 TLR4 IFNG ALB
219 legionellosis 10.5 TNF TLR4 TLR2 IL6
220 meconium aspiration syndrome 10.4 TNF IL6 IFNG
221 cryopyrin-associated periodic syndrome 10.4 IL6 CRP
222 vogt-koyanagi-harada disease 10.4 TLR4 TLR2 IL10 IFNG
223 chronic eosinophilic pneumonia 10.4 IL6 IL5 CCL5
224 anaerobic pneumonia 10.4 TNF IL6 CCL5
225 juvenile arthritis 10.4 IL6 IL10 CRP
226 niemann-pick disease 10.4 TLR4 IL6 IL10 CHIT1
227 ureteral disease 10.4 TNF IL6 ALB
228 stachybotrys chartarum 10.4 TNF IL6 CCL5
229 chronic active epstein-barr virus infection 10.4 IL2 IL10 IFNG CTLA4
230 neurosyphilis 10.4 TLR6 TLR2 TLR1 IL10
231 autoimmune vasculitis 10.4 TNF IL2 CRP
232 duodenal ulcer 10.4 TNF TLR4 IL6 IL10
233 chronic meningitis 10.4 IL5 CRP ALB
234 central nervous system lymphoma 10.4 TNF IL6 IL2 IL10
235 salivary gland disease 10.4 TNF IL6 IL2 IL10
236 myd88 deficiency 10.4 TLR6 TLR4 TLR2 TLR1
237 irak4 deficiency 10.4 TLR6 TLR4 TLR2 TLR1
238 staphylococcal toxic shock syndrome 10.4 TNF IGHE IFNG
239 optic neuritis 10.4 TNF IL6 IL10
240 chronic beryllium disease 10.4 TNF IFNG
241 shigellosis 10.4 TNF TLR4 IL10
242 acute myocarditis 10.4 TNF IL10 CRP
243 cytomegalovirus infection 10.4 TNF IL6 CCL5
244 aortitis 10.4 TNF IL6 CRP
245 chronic pyelonephritis 10.4 TLR4 CRP ALB
246 chondromalacia 10.4 TNF IL6 CRP
247 penicillin allergy 10.4 IL10 IGHE IFNG
248 alopecia 10.4 TNF IL2 IFNG CTLA4
249 congenital lymphedema 10.4 FOXC2 FLT4
250 acute graft versus host disease 10.4 TNF IL2 IL10 IFNG
251 granulomatous hepatitis 10.4 TNF CRP ALB
252 inflammatory and toxic neuropathy 10.4 TNF CRP ALB
253 aspiration pneumonitis 10.4 TNF CRP ALB
254 fuchs' heterochromic uveitis 10.4 IL6 IFNG
255 laryngitis 10.4 TNF IL6 CRP
256 hand, foot and mouth disease 10.4 TLR4 IL6 IL10 IFNG
257 ocular toxoplasmosis 10.4 TLR9 TLR1 IGHE
258 rheumatoid arthritis interstitial lung disease 10.4 TNF CRP
259 generalized atherosclerosis 10.4 IL6 CRP ALB
260 toxic megacolon 10.4 TNF CRP ALB
261 autoimmune disease of peripheral nervous system 10.4 TNF IL6 IL10 ALB
262 drug-induced lupus erythematosus 10.4 TNF IL6 IL10 ALB
263 acute cholangitis 10.4 IL6 CRP ALB
264 vaginal discharge 10.4 TNF IL6 CRP
265 posterior scleritis 10.4 TNF CRP
266 vernal keratoconjunctivitis 10.4 IL5 IGHE CCL5
267 autoimmune uveitis 10.4 TNF IL2 IL10 IFNG
268 pneumoconiosis 10.4 TNF IL6 IL10
269 tendinitis 10.4 TNF IL6 CRP
270 duodenitis 10.4 TNF CRP ALB
271 polyradiculopathy 10.4 TNF IL6 CRP
272 lactose intolerance 10.4 IL10 CRP ALB
273 scarlet fever 10.4 TNF CRP ALB
274 pyuria 10.4 IL6 CRP ALB
275 subacute thyroiditis 10.4 TNF IL6 CRP
276 retinal artery occlusion 10.4 IL6 IL10 CRP
277 encephalomalacia 10.4 TNF IL6 CRP
278 ectodermal dysplasia 1, hypohidrotic, x-linked 10.4 TNF IL6 IL10 ALB
279 opportunistic bacterial infectious disease 10.4 TNF IFNG CRP
280 eales disease 10.4 TNF IL6 IL10 IFNG
281 primary progressive multiple sclerosis 10.4 TNF IL10 CTLA4
282 chronic recurrent multifocal osteomyelitis 10.4 TNF IL6 CRP
283 hemorrhoid 10.4 TNF CRP ALB
284 nocardiosis 10.4 TNF IFNG CRP
285 acute proliferative glomerulonephritis 10.4 TNF CRP ALB
286 autoimmune lymphoproliferative syndrome 10.4 TNF IL2 IL10 CTLA4
287 varicocele 10.4 TNF IL6 ALB
288 hansen's disease 10.4
289 fungal meningitis 10.4 TNF IL6 IL10 IFNG
290 peptic ulcer disease 10.4 TNF IL10 ALB
291 prosthetic joint infection 10.4 TLR4 TLR2 IL6 CRP
292 toxic encephalopathy 10.4 TNF TLR4 IL6 ALB
293 milk allergy 10.4 TNF IL5 IL10 IGHE
294 kimura disease 10.4 IL5 IGHE CCL5
295 ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, autosomal recessive 10.4 TNF IL6 IL10 ALB
296 scalp dermatosis 10.4 TLR9 TLR6 TLR2 TLR1
297 hepatitis e 10.4 TNF IFNG ALB
298 facial nerve disease 10.4 TNF CRP ALB
299 hemophagocytic lymphohistiocytosis 10.4 TNF IL10 IFNG CTLA4
300 nodular goiter 10.4 IL6 CTLA4 CRP
301 tuberculous peritonitis 10.4 IFNG CRP ALB
302 microscopic colitis 10.4 TNF IL6 IL2 IFNG
303 kala-azar 1 10.4
304 orbital plasma cell granuloma 10.4 CTLA4 CRP
305 cryoglobulinemia 10.4 TNF IL6 IL10 IFNG
306 mixed connective tissue disease 10.4 TNF IL6 IL10 IFNG
307 mycosis fungoides 10.4 IL5 IL2 IFNG CTLA4
308 radiculopathy 10.4 IL6 IL5 IL10 CCL5
309 multidrug-resistant tuberculosis 10.4 TNF IL10 IFNG ALB
310 short syndrome 10.4 TNF IL6 CRP
311 smallpox 10.4 TNF IL2 IFNG
312 adult-onset still's disease 10.4 TNF IL6 CRP
313 neuromyelitis optica 10.4 IL6 IL5 CRP
314 paratyphoid fever 10.4 TNF IFNG CRP
315 cerebral palsy 10.4 TNF TLR4 IL6 IL10
316 constrictive pericarditis 10.4 IFNG CRP ALB
317 atopic keratoconjunctivitis 10.4 IL5 IL2 IGHE IFNG
318 aspiration pneumonia 10.4 IL6 CRP ALB
319 aggressive periodontitis 10.4 TNF TLR4 TLR2 IL6 IL10
320 petrositis 10.4 IFNG CRP
321 thymoma 10.4 TNF IL6 IL2 CTLA4
322 carotid stenosis 10.4 TNF IL10 CRP
323 coronavirus infectious disease 10.4 TNF IL6 CRP
324 peanut allergy 10.4 IL5 IL10 IGHE IFNG
325 allergic bronchopulmonary aspergillosis 10.4 IL5 IL10 IGHE IFNG
326 pulmonary artery disease 10.4 IL6 CRP ALB
327 chronic orbital inflammation 10.4 CTLA4 CRP
328 thyroiditis 10.4 TNF IL6 IL2 IL10 CTLA4
329 monocytic leukemia 10.4 TNF TLR4 IL6 IFNG
330 autoimmune disease of eyes, ear, nose and throat 10.4 TNF IL6 IL2 IL10 CTLA4
331 systolic heart failure 10.3 TNF IL6 CRP
332 severe cutaneous adverse reaction 10.3 TNF CTLA4 CRP
333 hypopyon 10.3 TNF IL6 IL10 CRP
334 epididymis disease 10.3 TNF TLR4 IL6 CRP
335 endogenous depression 10.3 IL6 IL2 CRP
336 viral encephalitis 10.3 TNF IL6 IL10 CCL5
337 rosacea 10.3 TNF TLR2 IL6 CRP
338 autoimmune pancreatitis 10.3 TNF TLR4 IL10 CTLA4 ALB
339 funisitis 10.3 TNF IL6 IL10 CRP
340 peptic ulcer perforation 10.3 CRP ALB
341 localized scleroderma 10.3 TNF IL6 IL2 CCL5
342 autoimmune disease of cardiovascular system 10.3 TNF TLR4 IL6 CRP
343 hepatic encephalopathy 10.3 TNF IL6 ALB
344 erysipelas 10.3 TNF IL6 IL2 CRP
345 henoch-schoenlein purpura 10.3 LGALS3BP CRP ALB
346 sezary's disease 10.3 IL5 IL2 IL10 IFNG CTLA4
347 mineral metabolism disease 10.3 IL6 CRP ALB
348 lens disease 10.3 TNF IL6 ALB
349 orofacial granulomatosis 10.3 TNF IL10 IFNG CCL5
350 biliary atresia 10.3 TNF IFNG ALB
351 hellp syndrome 10.3 TLR4 IL6 IL10 CRP
352 folliculitis 10.3 TNF IL5 IFNG CCL5
353 muckle-wells syndrome 10.3 TNF CRP ALB
354 secondary progressive multiple sclerosis 10.3 IL10 IFNG ALB
355 primary lymphedema 10.3 FOXC2 FLT4
356 placenta disease 10.3 TNF TLR4 IL6 CRP
357 gout 10.3 TNF TLR4 TLR2 IL6 ALB
358 suppression of tumorigenicity 12 10.3 TNF IL6 CTLA4 ALB
359 disseminated intravascular coagulation 10.3 TNF IL6 IL10 CRP
360 pericardial tuberculosis 10.3 IFNG CRP
361 fibromyalgia 10.3 TNF IL6 IL10 CRP
362 intermittent claudication 10.3 IL6 IL10 CRP ALB
363 coronary stenosis 10.3 TLR4 IL6 CRP ALB
364 immune system disease 10.3 TNF IL6 IL2 IL10 CTLA4
365 oral tuberculosis 10.3 TNF IL2 IFNG CRP
366 intussusception 10.3 IL6 FLT4 CRP ALB
367 hypotrichosis 1 10.3 TNF IL6 IL2 IL10 ALB
368 lymphoid interstitial pneumonia 10.3 TNF IL6 IL2 CRP
369 cholangitis, primary sclerosing 10.3 TNF TLR4 IL6 IL10 ALB
370 heart aneurysm 10.3 TNF IL6 CRP ALB
371 atrophic gastritis 10.3 TNF IL6 IL10
372 coronary aneurysm 10.3 TNF IL6 CRP ALB
373 sleep disorder 10.3 TNF IL6 CRP
374 pulmonary sarcoidosis 10.3 TNF IL2 IFNG CCL5
375 triiodothyronine receptor auxiliary protein 10.3
376 lymphangiectasis 10.3
377 background diabetic retinopathy 10.3 TNF IL6 CRP ALB
378 erythema multiforme 10.3 TNF IL6 IL5 IL2 IFNG
379 hantavirus hemorrhagic fever with renal syndrome 10.3 TNF IL6 CRP ALB
380 chronic inflammatory demyelinating polyradiculoneuropathy 10.3 IL10 IFNG CCL5 ALB
381 polyradiculoneuropathy 10.3 IL10 IFNG CCL5 ALB
382 myasthenia gravis 10.3 TNF IL2 IL10 IFNG CTLA4
383 aseptic meningitis 10.3 TNF IL10 IFNG CRP
384 lysosomal storage disease 10.3 TNF IL6 CHIT1 ALB
385 chorioretinitis 10.3 TNF IL6 IL2 IL10 IFNG
386 decubitus ulcer 10.3 TNF IL6 CRP ALB
387 compartment syndrome 10.3 TNF IL6 CRP ALB
388 pneumocystosis 10.3 TNF IL6 CRP ALB
389 fabry disease 10.3 TNF IL6 CRP CHIT1
390 allergic contact dermatitis 10.3 TNF IL6 IL5 IL10 IFNG
391 hypersensitivity vasculitis 10.3 TNF IL6 CRP ALB
392 cecal disease 10.3 TNF IL6 CRP ALB
393 x-linked monogenic disease 10.3 TNF IL6 IL2 IL10 ALB
394 hypersensitivity reaction type iii disease 10.3 TNF IL6 CRP ALB
395 intermediate uveitis 10.3 TNF IL6 IL2 IL10 IFNG
396 combat disorder 10.3 TLR9 TLR6 TLR4 TLR2 TLR1
397 autoimmune hepatitis 10.3 TNF IL6 IL10 CTLA4 ALB
398 lichen disease 10.3 TNF IL6 IL2 IL10 IFNG
399 mental depression 10.3 TNF IL6 CRP
400 autoimmune gastritis 10.3 TNF IL6 IL2 IL10 IFNG
401 chronic ulcer of skin 10.3 TNF IL6 CRP ALB
402 plasma protein metabolism disease 10.3 TNF IL6 CRP ALB
403 diverticulitis 10.3 TNF IL6 CRP ALB
404 subacute sclerosing panencephalitis 10.3 TNF IL6 IL2 IL10 IFNG
405 plasmodium vivax malaria 10.3 TNF IL6 IL2 IL10 IFNG
406 pharyngitis 10.3 TNF IL6 CRP ALB
407 complex regional pain syndrome 10.3 TNF IL6 IL2 IL10 IFNG
408 urinary tract obstruction 10.3 TNF CRP ALB
409 apnea, obstructive sleep 10.3 TNF IL6 CRP ALB
410 hepatic vascular disease 10.3 TNF IL6 CRP ALB
411 graft-versus-host disease 10.3 TNF IL6 IL2 IL10 IFNG
412 thyroid gland disease 10.3 IL6 CTLA4 CRP ALB
413 lymphopenia 10.3 IL6 IL2 IL10 IFNG CTLA4
414 cutaneous lupus erythematosus 10.3 TNF IL6 IL10 IFNG CTLA4
415 prediabetes syndrome 10.3 TNF IL6 CRP ALB
416 peripheral artery disease 10.3 TNF IL6 CRP
417 vaccinia 10.3 TNF TLR6 IL6 IL2 CTLA4
418 vein disease 10.3 TNF IL6 CRP ALB
419 mumps 10.3 TNF IL6 IL2 IL10 IFNG
420 granulomatous angiitis 10.3 IL5 CRP
421 intestinal obstruction 10.3 TNF IL6 CRP ALB
422 spondyloarthropathy 10.3 TNF IL6 IL2 IL10 IFNG
423 glomerulonephritis 10.3
424 ascaridiasis 10.3
425 hemorrhagic cystitis 10.3 TNF TLR4 LGALS3BP IL2 ALB
426 iron deficiency anemia 10.3 TNF IL6 CRP
427 chronic conjunctivitis 10.3 TNF IL6 IL5 IL10 IGHE
428 cranial nerve disease 10.3 TNF IL6 CRP ALB
429 hydrocephalus 10.3 TNF TLR4 TLR2 IL10 IFNG
430 retinal vascular disease 10.3 TNF IL6 CRP ALB
431 gastrointestinal tuberculosis 10.3 TNF IFNG CRP ALB
432 intestinal tuberculosis 10.3 TNF IFNG CRP ALB
433 diphtheria 10.3 TNF IL5 IL2 IFNG ALB
434 abdominal tuberculosis 10.3 TNF IFNG CRP ALB
435 listeriosis 10.3 TNF TLR4 TLR2 IL6 IL2 IL10
436 drug allergy 10.3 IL5 IGHE CRP ALB
437 miliary tuberculosis 10.3 TNF IFNG CRP ALB
438 aicardi-goutieres syndrome 10.3 TLR9 TLR6 TLR4 TLR2 TLR1
439 sickle cell anemia 10.3 TNF IL6 CRP ALB
440 bone resorption disease 10.3 TNF IL6 CRP ALB
441 idiopathic neutropenia 10.3 TNF TLR4 IL6 IL10 CCL5
442 bone remodeling disease 10.3 TNF IL6 CRP ALB
443 cystitis 10.3 TNF TLR4 IL6 IL2 CRP
444 uremia 10.3 TNF IL6 CRP ALB
445 urethritis 10.3 TNF TLR4 TLR2 IL6 CRP
446 bullous pemphigoid 10.3 TNF IL5 IGHE CCL5
447 fallopian tube disease 10.3 TNF TLR4 TLR2 IL6 CRP
448 ancylostomiasis 10.3
449 sebaceous gland disease 10.3 TNF TLR4 TLR2 IL6 CRP
450 esophagitis 10.3 TNF IL6 IL5 IL10 CCL5
451 bile duct disease 10.3 TNF IL6 CRP ALB
452 biliary tract disease 10.2 TNF IL6 CRP ALB
453 muscular disease 10.2 TNF IL6 CRP ALB
454 pertussis 10.2 TNF TLR4 IL6 IL10 CCL5
455 gestational diabetes 10.2 TNF IL6 CRP ALB
456 chorioamnionitis 10.2 TNF TLR4 IL6 IL10 CRP
457 clonorchiasis 10.2 TNF IL2 IL10 IGHE IFNG
458 optic nerve disease 10.2 TNF IL6 CRP ALB
459 japanese encephalitis 10.2
460 spotted fever 10.2 TNF IL10 IFNG CTLA4 CCL5
461 spotted fever rickettsiosis 10.2 TNF IL10 IFNG CTLA4 CCL5
462 corneal disease 10.2 TNF TLR4 TLR2 IL6 IL10 ALB
463 cervicitis 10.2 TNF TLR9 TLR4 TLR2 IL6 IL2
464 speech and communication disorders 10.2 TNF IL6 CRP ALB
465 bacterial vaginosis 10.2 TNF TLR9 TLR4 TLR2 IL6 IL10
466 penile disease 10.2 TNF TLR9 TLR4 TLR2 IL6 IL2
467 multicentric castleman disease 10.2 IL6 IL5 IL10 IFNG CRP
468 castleman disease 10.2 IL6 IL5 IL10 IFNG CRP
469 polyneuropathy 10.2 TNF IL6 CRP ALB
470 infective endocarditis 10.2 TNF TLR6 TLR2 IL6 CRP
471 endophthalmitis 10.2 TNF TLR2 IL6 CRP ALB
472 scleritis 10.2 TNF IL5 IFNG CTLA4 CRP
473 familial hypercholesterolemia 10.2 TNF IL6 CRP ALB
474 stevens-johnson syndrome/toxic epidermal necrolysis 10.2 TLR9 IL5 IL2 IFNG CCL5
475 tropical spastic paraparesis 10.2 IL6 IL2 IL10 IFNG CCL5
476 stomatitis 10.2 TNF TLR4 IL6 IL2 IL10 IFNG
477 chronic mucocutaneous candidiasis 10.2 TNF TLR2 IL6 IL5 IL10 IFNG
478 relapsing polychondritis 10.2 IL6 IL2 IL10 IFNG CRP
479 glucose intolerance 10.2 TNF IL6 CRP ALB
480 dengue disease 10.2
481 cytokine deficiency 10.2
482 fatty liver disease 10.2 TNF TLR4 IL6 CRP ALB
483 congestive heart failure 10.2 TNF IL6 CRP ALB
484 kidney cancer 10.2 TNF IL2 IFNG FLT4 ALB
485 hair disease 10.2 TNF IL6 IL2 IL10 CTLA4 ALB
486 cerebrovascular disease 10.2 TNF TLR4 IL6 CRP
487 pancreatitis 10.2 TNF IL6 IL10 CRP ALB
488 african tick-bite fever 10.2 TNF IL6 IL10 IFNG CCL5
489 arteries, anomalies of 10.2 TNF IL6 CRP ALB
490 x-linked recessive disease 10.2 TNF IL6 IL2 IL10 CTLA4 ALB
491 autoimmune disease of exocrine system 10.2 TNF TLR9 IL6 IL10 CRP
492 intracranial berry aneurysm 10.2 TNF TLR4 IL6 CRP ALB
493 viral meningitis 10.2 IL6 IFNG CRP CCL5
494 skeletal tuberculosis 10.2 IFNG CRP
495 mouth disease 10.2 TLR4 IL6 IL10 IFNG CRP
496 sleep apnea 10.2 TNF IL6 IL10 CRP ALB
497 anogenital venereal wart 10.2 TLR9 TLR6 TLR4 TLR2 TLR1 IL2
498 ascending cholangitis 10.2 CRP ALB
499 blood platelet disease 10.2 TNF IL6 IL2 CRP ALB
500 autoimmune disease of skin and connective tissue 10.2 TNF IL6 IL2 IL10 IFNG CTLA4
501 deficiency anemia 10.2 TNF IL6 CRP ALB
502 neuritis 10.2 TNF IL6 IL10 IFNG CCL5
503 autoimmune disease of endocrine system 10.2 TNF IL6 IL2 IL10 IFNG CTLA4
504 potocki-shaffer syndrome 10.2 TNF TLR9 IL6 IL10 CRP
505 inherited metabolic disorder 10.2 TNF TLR4 IL6 CRP ALB
506 scleral disease 10.2 TNF IL6 IL2 IFNG CRP
507 endometritis 10.2 TNF TLR6 TLR4 TLR2 TLR1 IL6
508 constipation 10.2 TNF IL6 CRP ALB
509 hepatitis a 10.2 TNF TLR4 IL10 IFNG CTLA4 ALB
510 central nervous system vasculitis 10.2 TNF IL6 IFNG CTLA4 CRP
511 atherosclerosis susceptibility 10.2 TNF TLR4 IL6 CRP ALB
512 hyperthyroidism 10.2 TNF IL6 CTLA4 CRP ALB
513 urinary system disease 10.2 TNF IL6 CRP ALB
514 alopecia areata 10.2 TNF IL6 IL2 IL10 IFNG CTLA4
515 spondylitis 10.2 TNF IL6 IL10 IFNG CRP
516 non-alcoholic steatohepatitis 10.2 TNF TLR9 TLR4 TLR2 IL6 ALB
517 purpura 10.2 TNF IL6 IL10 IFNG CRP
518 glucose metabolism disease 10.2 TNF IL6 IL10 CRP ALB
519 vaginitis 10.2 TNF TLR4 TLR2 IL6 IL10 CCL5
520 ileus 10.2 TNF IL6 IL10 IFNG CRP
521 acquired metabolic disease 10.2 TNF IL6 IL10 CRP ALB
522 splenomegaly 10.2
523 herpes simplex 10.2 TNF TLR9 TLR2 IL6 CCL5
524 ileitis 10.2 TNF TLR4 TLR2 IL6 IL10 CCL5
525 parenchymatous neurosyphilis 10.2 TLR6 TLR1
526 respiratory allergy 10.2 TNF TLR4 IL6 IL5 IL10 CCL5
527 lipoprotein quantitative trait locus 10.2 TNF IL6 IL10 CRP ALB
528 acute pyelonephritis 10.2 IL6 IL10 IFNG CRP ALB
529 gingival disease 10.2 TNF TLR4 TLR2 IL6 IL10 CRP
530 systemic scleroderma 10.2 TNF IL6 IL10 IFNG CRP
531 preterm premature rupture of the membranes 10.2 TNF TLR4 TLR2 IL6 IL10 CRP
532 cystic fibrosis 10.2 TNF TLR4 TLR2 IL6 IL10 ALB
533 familial mediterranean fever 10.1 TNF TLR4 TLR2 IL6 IL10 CRP
534 ankylosing spondylitis 1 10.1 CRP ALB
535 human immunodeficiency virus type 1 10.1 TNF IL2 IL10 IFNG CCL5
536 brain edema 10.1 IL6 IL2 IFNG CRP ALB
537 lung abscess 10.1 TNF IL6 IFNG CRP ALB
538 viral pneumonia 10.1 TNF IL6 IL10 CRP CCL5
539 migraine with or without aura 1 10.1 TNF IL6 IL10 CRP ALB
540 extrinsic allergic alveolitis 10.1 IL6 IL10 IGHE CCL5 ALB
541 allergic conjunctivitis 10.1 TNF IL5 IL2 IL10 IGHE IFNG
542 pericardium disease 10.1 TNF IL6 IFNG CRP ALB
543 allergic rhinitis 10.1 IL5 IL10 IGHE IFNG CCL5
544 pancreatic adenocarcinoma 10.1 TNF IL6 IL2 IL10 FLT4 ALB
545 breast cancer 10.1
546 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
547 west nile virus 10.1
548 nephrotic syndrome 10.1
549 pleural disease 10.1 TNF IL6 IFNG CRP ALB
550 omenn syndrome 10.1 TNF IL5 IL2 IL10 IGHE IFNG
551 nutritional deficiency disease 10.1 IL6 CRP ALB
552 stroke, ischemic 10.1 TNF TLR4 IL6 CRP ALB
553 influenza 10.1 TNF TLR4 IL6 IFNG CCL5
554 cardiovascular system disease 10.1 TNF TLR4 IL6 CRP ALB
555 blood group, globoside system 10.1 TNF TLR4 TLR2 IL6 CRP ALB
556 anus disease 10.1 TNF TLR9 TLR4 TLR2 IL6 IL2
557 hypothyroidism 10.1 TNF IL2 CTLA4 CRP ALB
558 pyelitis 10.1 TNF TLR4 TLR2 IL6 CRP ALB
559 herpes zoster 10.1 TNF TLR2 IL2 IL10 IFNG CRP
560 endocardium disease 10.1 TNF TLR4 TLR2 IL6 CRP ALB
561 bronchopneumonia 10.1 TNF TLR4 IL6 IL10 CRP ALB
562 intestinal perforation 10.1 TNF TLR4 IL6 CTLA4 CRP ALB
563 stomach disease 10.1 TNF TLR4 IL6 IL10 CRP ALB
564 leukemia, chronic lymphocytic 10.1 TNF TLR9 IL6 IL2 IL10 CTLA4
565 obstructive jaundice 10.1 TNF TLR4 IL6 IL2 CRP ALB
566 rubella 10.1 TNF TLR4 IL6 IL5 IL2 IL10
567 spinal cord disease 10.1 TNF IL6 IL2 IL10 CRP ALB
568 acute pancreatitis 10.1 TNF TLR4 IL6 IL10 CRP ALB
569 blood coagulation disease 10.1 TNF IL6 IL2 IL10 CRP ALB
570 mycoplasma pneumoniae pneumonia 10.1 TNF TLR2 IL6 IL10 IFNG CRP
571 overnutrition 10.1 TNF TLR4 IL6 IL10 CRP ALB
572 kawasaki disease 10.1 TNF IL6 IL2 IL10 CRP ALB
573 paranasal sinus disease 10.1 TNF IL6 IL5 IL10 IFNG CRP
574 bacteriuria 10.1 TLR4 TLR2 TLR1 IL6 CRP ALB
575 intestinal disease 10.1 TNF TLR4 IL6 IL10 CRP ALB
576 fibrosis of extraocular muscles, congenital, 1 10.1
577 dracunculiasis 10.1
578 scabies 10.1
579 epididymo-orchitis 10.1
580 48,xyyy 10.1
581 hashimoto thyroiditis 10.1 TNF IL6 IL5 IL2 IL10 IFNG
582 endometrial disease 10.1 TNF TLR6 TLR4 TLR2 TLR1 IL6
583 myocarditis 10.1 TNF TLR4 IL6 IL2 IL10 IFNG
584 extrapulmonary tuberculosis 10.1 TNF TLR2 IL10 IFNG CRP ALB
585 alcoholic liver cirrhosis 10.1 TNF TLR9 TLR4 TLR2 IL6 IL10
586 lipid storage disease 10.1 TNF TLR4 IL6 CRP CHIT1 ALB
587 demyelinating disease 10.1 TNF IL6 IL2 IL10 IFNG CCL5
588 major depressive disorder 10.1 TNF IL6 IL10 IFNG CRP
589 central nervous system disease 10.1 TNF IL6 IFNG ALB
590 lymphoma, non-hodgkin, familial 10.1 TNF IL6 IL2 IL10 CTLA4
591 superficial basal cell carcinoma 10.1 TNF TLR9 TLR6 TLR4 TLR2 TLR1
592 yellow nail syndrome 10.1 FOXC2 ALB
593 chronic kidney disease 10.1 TNF TLR4 IL6 IL10 CRP ALB
594 sclerosing cholangitis 10.1 TNF TLR9 TLR4 IL6 IL2 IL10
595 rheumatic fever 10.1 TNF TLR2 IL6 IL2 IL10 IFNG
596 human immunodeficiency virus infectious disease 10.1 TNF TLR9 IL2 IL10 IFNG CCL5
597 pre-eclampsia 10.0 TNF TLR4 IL6 IL10 CRP ALB
598 melioidosis 10.0 TNF TLR4 TLR2 TLR1 IL6 IL10
599 takayasu arteritis 10.0 TNF IL6 IL2 IL10 CRP CCL5
600 granulomatosis with polyangiitis 10.0 TNF TLR9 TLR4 TLR2 IL5 CTLA4
601 combined t cell and b cell immunodeficiency 10.0 TNF IL6 IL2 IL10 IFNG CTLA4
602 invasive aspergillosis 10.0 TLR9 TLR6 TLR4 TLR2 TLR1 IL10
603 hypercarotenemia and vitamin a deficiency, autosomal dominant 10.0
604 sleeping sickness 10.0
605 keratomalacia 10.0
606 rift valley fever 10.0
607 coccidioidomycosis 10.0
608 angioedema 10.0
609 lymphangiosarcoma 10.0
610 lymphocele 10.0
611 t-cell lymphoblastic leukemia/lymphoma 10.0
612 47,xyy 10.0
613 leukemia, t-cell, chronic 10.0
614 rare lymphatic malformation 10.0
615 dysentery 10.0 TNF TLR4 TLR2 IL6 IL10 CRP
616 aphthous stomatitis 10.0 TNF TLR4 TLR2 IL6 IL5 IL2
617 myelodysplastic syndrome 10.0 TNF TLR2 IL6 IL2 IL10 IFNG
618 bacterial sepsis 10.0 TNF TLR9 TLR4 TLR2 IL6 IL10
619 connective tissue disease 10.0 TNF IL6 IL10 IFNG CRP ALB
620 contact dermatitis 10.0 TNF TLR4 TLR2 IL6 IL5 IL2
621 irritable bowel syndrome 10.0 TNF TLR9 TLR4 TLR2 IL6 IL10
622 osteomyelitis 10.0 TNF TLR4 TLR2 IL6 IL10 IFNG
623 gingivitis 10.0 TNF TLR2 IL6 IL2 IL10 IFNG
624 reactive arthritis 10.0 TNF TLR4 TLR2 IL6 IL10 IFNG
625 arteriosclerosis 10.0 TLR4 IL6 IL10 IFNG CRP CCL5
626 periodontitis 10.0 TNF TLR4 TLR2 IL6 IL10 IFNG
627 relapsing-remitting multiple sclerosis 10.0 TNF TLR4 IL6 IL2 IL10 IFNG
628 leukemia, acute myeloid 10.0 TNF IL6 IL2 IL10 IFNG CTLA4
629 brucellosis 10.0 TNF TLR4 IL6 IL2 IL10 IFNG
630 candidiasis 10.0 TNF TLR4 TLR2 IL6 IL2 IL10
631 macular degeneration, age-related, 1 10.0 TNF TLR4 TLR2 IL6 FLT4 CRP
632 sarcoidosis 1 10.0 TNF IL2 IFNG CRP CHIT1 CCL5
633 temporal arteritis 10.0 TNF IL6 IFNG CTLA4 CRP CCL5
634 ulcerative colitis 10.0 TNF TLR4 IL6 IL2 IL10 IFNG
635 uveal disease 10.0 TNF IL6 IL2 IL10 IFNG CTLA4
636 pelvic inflammatory disease 9.9 TLR6 TLR4 TLR2 TLR1 IL2 IFNG
637 septic arthritis 9.9 TNF TLR9 TLR4 TLR2 IL6 IFNG
638 angiosarcoma 9.9
639 sparganosis 9.9
640 giardiasis 9.9
641 st. louis encephalitis 9.9
642 hemopericardium 9.9
643 goiter 9.9
644 leukemia 9.9
645 trichuriasis 9.9
646 keratosis 9.9
647 impotence 9.9
648 enthesopathy 9.9
649 immune-complex glomerulonephritis 9.9
650 inflammatory breast carcinoma 9.9
651 trichinosis 9.9
652 chronic pain 9.9
653 common cold 9.9 TNF TLR4 TLR2 IL6 IL5 IL10
654 amyotrophic lateral sclerosis 1 9.9 TNF TLR6 TLR4 TLR2 TLR1 IL6
655 lyme disease 9.9 TNF TLR9 TLR6 TLR2 TLR1 IL6
656 autoimmune disease of blood 9.9 TNF IL6 IL5 IL2 IL10 CTLA4
657 chronic fatigue syndrome 9.9 TNF TLR4 IL6 IL5 IL2 IL10
658 leukocyte disease 9.9 TNF IL6 IL5 IL2 IL10 CTLA4
659 cholangitis 9.9 TNF TLR4 IL6 IL2 IL10 CTLA4
660 toxic shock syndrome 9.9 TNF TLR4 TLR2 IL6 IL2 IL10
661 bronchiolitis obliterans 9.9 TNF TLR4 TLR2 IL6 IL10 IFNG
662 severe acute respiratory syndrome 9.9 TNF IL6 IL2 IL10 IFNG CRP
663 aplastic anemia 9.9 TNF TLR9 IL6 IL2 IL10 IFNG
664 middle ear disease 9.9 TNF TLR9 TLR4 TLR2 IL6 IL10
665 chlamydia pneumonia 9.9 TNF TLR6 TLR4 TLR2 TLR1 IL6
666 hyper ige syndrome 9.9 TNF TLR9 TLR4 TLR2 IL6 IL10
667 allergic asthma 9.9 TLR4 TLR2 IL5 IL10 IGHE IFNG
668 bacterial pneumonia 9.8 TNF TLR9 TLR4 TLR2 IL6 IL10
669 acute cystitis 9.8 TNF TLR4 TLR2 TLR1 IL6 IL10
670 alcoholic hepatitis 9.8 TNF TLR9 TLR4 TLR2 IL6 IL10
671 q fever 9.8 TNF TLR4 TLR2 TLR1 IL6 IL10
672 primary systemic mycosis 9.8 TNF TLR2 IL6 IL2 IL10 IFNG
673 measles 9.8 TNF TLR9 TLR4 TLR2 IL6 IL2
674 colitis 9.8 TNF TLR9 TLR4 TLR2 IL6 IL2
675 appendicitis 9.8 TNF TLR4 IL6 IL2 IL10 IFNG
676 common variable immunodeficiency 9.8 TNF TLR9 TLR2 IL6 IL5 IL2
677 leptospirosis 9.8 TNF TLR2 TLR1 IL6 IL2 IL10
678 neutropenia 9.8 TNF TLR4 IL6 IL2 IL10 IFNG
679 conjunctivitis 9.8 TNF IL6 IL5 IL2 IL10 IGHE
680 juvenile rheumatoid arthritis 9.8 TNF IL6 IL2 IL10 IFNG CTLA4
681 upper respiratory tract disease 9.8 TNF TLR4 TLR2 IL6 IL5 IL2
682 testicular disease 9.8 TNF TLR4 TLR2 TLR1 IL6 IL2
683 food allergy 9.8 TNF TLR4 TLR2 IL5 IL10 IGHE
684 osteoporosis 9.8 TNF TLR4 IL6 IL2 IL10 IFNG
685 antiphospholipid syndrome 9.8 TNF TLR4 CRP
686 tonsillitis 9.8 TNF TLR9 TLR4 TLR2 TLR1 IL6
687 non-alcoholic fatty liver disease 9.8 TNF TLR6 TLR4 TLR1 IL6 IL10
688 bladder cancer 9.8
689 epidermoid cysts 9.8
690 melkersson-rosenthal syndrome 9.8
691 papillomatosis, confluent and reticulated 9.8
692 testicular torsion 9.8
693 tinea imbricata 9.8
694 budd-chiari syndrome 9.8
695 pars planitis 9.8
696 anxiety 9.8
697 buruli ulcer 9.8
698 leukemia, acute lymphoblastic 9.8
699 dengue virus 9.8
700 membranous nephropathy 9.8
701 melanoma, cutaneous malignant 10 9.8
702 angiostrongyliasis 9.8
703 thelaziasis 9.8
704 intestinal schistosomiasis 9.8
705 sexual disorder 9.8
706 lymphoma 9.8
707 yaws 9.8
708 protein-losing enteropathy 9.8
709 interstitial nephritis 9.8
710 paragonimiasis 9.8
711 bubonic plague 9.8
712 western equine encephalitis 9.8
713 myiasis 9.8
714 gnathomiasis 9.8
715 heart disease 9.8
716 cardiac tamponade 9.8
717 infant gynecomastia 9.8
718 visual epilepsy 9.8
719 capillariasis 9.8
720 gynecomastia 9.8
721 guillain-barre syndrome 9.8
722 focal segmental glomerulosclerosis 9.8
723 endemic goiter 9.8
724 opisthorchiasis 9.8
725 nodular nonsuppurative panniculitis 9.8
726 breast fibroadenoma 9.8
727 squamous cell carcinoma 9.8
728 status epilepticus 9.8
729 giant cell reparative granuloma 9.8
730 melanoma 9.8
731 hypogonadism 9.8
732 papilloma 9.8
733 adenocarcinoma 9.8
734 granulomatous orchitis 9.8
735 gallbladder cancer 9.8
736 mammary paget's disease 9.8
737 gallbladder adenocarcinoma 9.8
738 hypertrichosis 9.8
739 ebola hemorrhagic fever 9.8
740 pustulosis of palm and sole 9.8
741 mucoepidermoid carcinoma 9.8
742 proliferative glomerulonephritis 9.8
743 mesangial proliferative glomerulonephritis 9.8
744 ovarian cyst 9.8
745 infertility 9.8
746 paraplegia 9.8
747 b-cell lymphoma 9.8
748 actinomycosis 9.8
749 dermatophytosis 9.8
750 intracranial hypertension 9.8
751 babesiosis 9.8
752 noma 9.8
753 glioma 9.8
754 gnathostoma infection 9.8
755 koro 9.8
756 prurigo nodularis 9.8
757 depression 9.8
758 seizure disorder 9.8
759 posttransplant acute limbic encephalitis 9.8
760 glial tumor 9.8
761 argyria 9.8
762 pik3ca-related overgrowth syndrome 9.8
763 gastroenteritis 9.8 TNF TLR9 IL6 IL5 IL10 IFNG
764 extrinsic cardiomyopathy 9.8 TNF TLR9 TLR4 TLR2 IL6 IL2
765 esophageal cancer 9.8 TNF TLR4 IL6 IL2 IL10 IFNG
766 paracoccidioidomycosis 9.7 TNF TLR4 TLR2 IL6 IL5 IL2
767 chlamydia 9.7 TNF TLR9 TLR4 TLR2 IL6 IL5
768 lymph node disease 9.7 TNF TLR4 TLR2 IL6 IL2 IL10
769 pyelonephritis 9.7 TNF TLR4 IL6 IL10 IFNG CRP
770 autoimmune disease of gastrointestinal tract 9.7 TNF TLR4 IL6 IL2 IL10 IFNG
771 perinatal necrotizing enterocolitis 9.7 TNF TLR9 TLR6 TLR4 TLR2 TLR1
772 streptococcus pneumonia 9.7 TNF TLR9 TLR6 TLR4 TLR2 TLR1
773 pulmonary disease, chronic obstructive 9.7 TNF TLR4 TLR2 IL6 IL5 IL10
774 bacterial meningitis 9.7 TNF TLR9 TLR4 TLR2 IL6 IL10
775 dilated cardiomyopathy 9.7 TNF TLR4 IL6 IL2 IL10 IFNG
776 primary biliary cirrhosis 9.7 TNF TLR9 TLR4 IL6 IL5 IL2
777 rhinitis 9.6 TNF TLR4 IL6 IL5 IL10 IGHE
778 cervical cancer 9.6 TNF TLR9 TLR4 IL6 IL2 IL10
779 herpangina 9.6 TNF TLR9 TLR6 TLR4 TLR2 TLR1
780 psoriatic arthritis 9.6 TNF TLR9 TLR4 TLR2 IL6 IL2
781 salmonellosis 9.6 TNF TLR9 TLR6 TLR4 TLR2 TLR1
782 interstitial lung disease 9.6 TNF IL6 IL5 IL10 IFNG CRP
783 myocardial infarction 9.6 TNF TLR4 TLR2 IL6 IL10 IFNG
784 respiratory failure 9.6 TNF TLR4 IL6 IL5 IL10 IGHE
785 hypersensitivity reaction type iv disease 9.6 TNF TLR2 IL6 IL2 IL10 IFNG
786 conjunctival disease 9.6 TNF TLR4 TLR2 IL6 IL5 IL2
787 crohn's disease 9.6 TNF TLR9 TLR4 TLR2 IL6 IL2
788 splenic disease 9.6 TNF TLR9 TLR4 TLR2 IL6 IL2
789 viral hepatitis 9.6 TNF TLR9 TLR4 TLR2 IL6 IL2
790 chickenpox 9.6 TNF TLR9 TLR2 IL6 IL2 IL10
791 peripheral nervous system disease 9.6 TNF TLR4 TLR2 TLR1 IL6 IL2
792 nasal cavity disease 9.5 TNF TLR9 TLR4 TLR2 IL6 IL5
793 viral infectious disease 9.4 TNF TLR9 TLR4 TLR2 TLR1 IL6
794 thrombocytopenia 9.4 TNF TLR9 TLR4 TLR2 IL6 IL2
795 aspergillosis 9.4 TNF TLR9 TLR6 TLR4 TLR2 TLR1
796 rectal disease 9.4 TNF TLR9 TLR6 TLR4 TLR2 TLR1
797 rheumatoid arthritis 9.4 TNF TLR9 TLR4 TLR2 IL6 IL2
798 vaginal disease 9.4 TNF TLR9 TLR6 TLR4 TLR2 TLR1
799 pulmonary fibrosis, idiopathic 9.4 TNF TLR9 TLR4 TLR2 IL6 IL5
800 autoimmune disease of central nervous system 9.4 TNF TLR9 TLR4 TLR2 IL6 IL5
801 myeloma, multiple 9.3 TNF TLR9 TLR4 IL6 IL2 IL10
802 diabetes mellitus, noninsulin-dependent 9.3 TNF TLR9 TLR6 TLR4 TLR2 TLR1
803 commensal bacterial infectious disease 9.3 TNF TLR9 TLR4 TLR2 TLR1 IL6
804 eye disease 9.3 TNF TLR4 TLR2 IL6 IL5 IL2
805 coccidiosis 9.3 TNF TLR9 TLR6 TLR4 TLR2 TLR1
806 meningitis 9.3 TNF TLR9 TLR4 TLR2 IL6 IL5
807 nose disease 9.3 TNF TLR9 TLR4 TLR2 IL6 IL5
808 multiple sclerosis 9.2 TNF TLR9 TLR4 TLR2 IL6 IL5
809 bronchiolitis 9.2 TNF TLR9 TLR6 TLR4 TLR2 TLR1
810 integumentary system disease 9.2 TNF TLR9 TLR4 TLR2 TLR1 IL6
811 opportunistic mycosis 9.2 TNF TLR9 TLR6 TLR4 TLR2 TLR1
812 fungal infectious disease 9.2 TNF TLR9 TLR6 TLR4 TLR2 TLR1
813 bone inflammation disease 9.1 TNF TLR9 TLR6 TLR4 TLR2 TLR1
814 autoimmune disease of musculoskeletal system 9.1 TNF TLR9 TLR6 TLR4 TLR2 TLR1
815 body mass index quantitative trait locus 11 9.1 TNF TLR9 TLR6 TLR4 TLR2 TLR1
816 pneumonia 9.1 TNF TLR9 TLR6 TLR4 TLR2 IL6
817 diabetes mellitus 9.0 TNF TLR9 TLR4 TLR2 IL6 IL2
818 otitis media 9.0 TNF TLR4 TLR2 TLR1 IL6 IL5
819 hypertension, essential 9.0 TNF TLR9 TLR6 TLR4 TLR2 TLR1
820 diabetes mellitus, type i 9.0 TNF TLR9 TLR6 TLR4 TLR2 TLR1
821 celiac disease 1 9.0 TNF TLR9 TLR6 TLR4 TLR2 TLR1
822 behcet syndrome 9.0 TNF TLR9 TLR6 TLR4 TLR2 TLR1
823 bronchial disease 8.9 TNF TLR9 TLR6 TLR4 TLR2 TLR1
824 inflammatory bowel disease 8.8 TNF TLR9 TLR6 TLR4 TLR2 TLR1
825 primary bacterial infectious disease 8.8 TNF TLR9 TLR6 TLR4 TLR2 TLR1
826 colorectal cancer 8.8 TNF TLR9 TLR6 TLR4 TLR2 TLR1

Graphical network of the top 20 diseases related to Filariasis:



Diseases related to Filariasis

Symptoms & Phenotypes for Filariasis

MGI Mouse Phenotypes related to Filariasis:

45 (showing 9, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.3 ALB CCL5 CHIT1 CRP CTLA4 FLT4
2 digestive/alimentary MP:0005381 10.25 ALB CTLA4 FLT4 FOXC2 IFNG IL10
3 homeostasis/metabolism MP:0005376 10.24 ALB CRP CTLA4 FLT4 FOXC2 IFNG
4 cardiovascular system MP:0005385 10.23 ALB CRP CTLA4 FLT4 FOXC2 IFNG
5 hematopoietic system MP:0005397 10.22 CCL5 CTLA4 IFNG IL10 IL2 IL5
6 liver/biliary system MP:0005370 10.03 ALB CTLA4 FLT4 FOXC2 IFNG IL10
7 muscle MP:0005369 9.81 ALB FLT4 FOXC2 IFNG IL10 IL6
8 neoplasm MP:0002006 9.61 ALB IFNG IL10 IL2 IL5 IL6
9 respiratory system MP:0005388 9.32 CTLA4 FOXC2 IFNG IL10 IL2 IL5

Drugs & Therapeutics for Filariasis

Drugs for Filariasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 32, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4 90-89-1 3052
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3 Antimalarials Phase 4
4 Vitamins Phase 3
5 Milbemycin Phase 3
6
Reslizumab Approved, Investigational Phase 2 241473-69-8
7
Dihydroartemisinin Experimental, Investigational Phase 2 71939-50-9 6918483
8
Piperaquine Experimental, Investigational Phase 2 4085-31-8 5079497
9 Respiratory System Agents Phase 2
10 Immunoglobulins Phase 2
11 Antibodies Phase 2
12 Anti-Asthmatic Agents Phase 2
13 Antibodies, Monoclonal Phase 2
14 Protein Kinase Inhibitors Phase 2
15 Imatinib Mesylate Phase 2 220127-57-1 123596
16
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
17
Emodepside Investigational, Vet_approved Phase 1 155030-63-0
18 Pharmaceutical Solutions Phase 1
19 Toltrazuril Phase 1
20
Polidocanol Approved 9002-92-0
21
Sodium citrate Approved, Investigational 68-04-2
22
Mebendazole Approved, Vet_approved 31431-39-7 4030
23
Piperazine Approved, Vet_approved 110-85-0 4837
24
Permethrin Approved, Investigational 52645-53-1 40326
25
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
26 Anesthetics
27 Sclerosing Solutions
28 Citrate
29 Piperazine citrate
30 DMP 777 157341-41-8
31 Liver Extracts
32 Insect Repellents

Interventional clinical trials:

(showing 62, show less)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Completed NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
3 Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection: Double Blind Randomised Clinical Trial (RCT) to Study the Efficacy of Different Co-administration and Sequential Administration Completed NCT02005653 Phase 4 Diethylcarbamazine;Albendazole;Doxycycline
4 Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
5 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
6 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
7 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
8 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
9 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
10 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
11 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Recruiting NCT03014167 Phase 3 Albendazole
12 A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis Recruiting NCT04410406 Phase 3 IA (IVM+ ABZ);MoxA (Mox + ABZ);IDA (IVM + DEC + ABZ);MoxDA (Mox + DEC + ABZ)
13 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929134 Phase 3 Doxycycline;Placebo
14 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929121 Phase 3 Doxycycline;Placebo
15 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02927496 Phase 3 Doxycycline;Placebo
16 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
17 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
18 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
19 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
20 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
21 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
22 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL) Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
23 A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection Completed NCT01111305 Phase 2 Reslizumab;Diethylcarbamazine
24 A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19 Recruiting NCT04381884 Phase 2 IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
25 A Double-Blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa (A Pilot Study) Active, not recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
26 Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis Enrolling by invitation NCT04188301 Phase 2 IVM w/ ALB;Single dose of IDA;Three daily doses of IDA
27 Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms Not yet recruiting NCT04407507 Phase 2 Ivermectin;Placebo
28 A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) or matching placebo
29 A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
30 Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
31 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
32 Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study. Unknown status NCT02082613
33 Exhaled NO Testing in Filariasis Completed NCT01628497
34 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
35 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
36 Research for Elimination of Human Filariasis Completed NCT00145223
37 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
38 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
39 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
40 Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators Completed NCT03352206 2 drug dose - DA;3 drug dose - IDA
41 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
42 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
43 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
44 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
45 Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection Completed NCT00344279
46 Gaps in Helminth Control: Safety and Efficacy of Drug Combinations Against Triple Infections Completed NCT01050517 albendazole + ivermectin + praziquantel;albendazole + ivermectin + (1 week later) praziquantel
47 Regulation of Innate and Adaptive Immune Responses in Individuals Infected Concurrently With Malarial and Filarial Parasites Completed NCT00341666
48 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
49 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
50 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252
51 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
52 Community-Directed Treatment in the Control of Soil-Transmitted Helminths Among Children Aged 12-59 Months in Mazabuka District of Zambia Completed NCT00349323
53 Study of Patients With Known or Suspected Infection With Strongyloides Stercoralis Completed NCT00001245
54 Veron Scabies Education and Eradication Program Completed NCT00604084 Ivermectin;Permethrin 5% lotion
55 Comparison Trial Between Two Repellent Products and a Positive Control Against Culicoides Nubeculosus Midges Completed NCT04028180
56 Effect of Filarial Infection on Antigen-Specific Immune Responses in Latent Tuberculosis Recruiting NCT01547884
57 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Recruiting NCT03683745
58 When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to Recruiting NCT04124250
59 Host Response to Infection and Treatment in the Filarial Diseases of Humans Recruiting NCT00001230
60 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Enrolling by invitation NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
61 Spontaneous Antigenemia in Loiasis, A Study of the Loiasis Antigens Responsible for Cross-reactivity in the Rapid Diagnostic Test for Lymphatic Filariasis Suspended NCT04258670
62 Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study Terminated NCT01213576 Albendazole 400mg and ivermectin 200mcg/kg;Albendazole and ivermectin;Albendazole 400mg and ivermectin 200mcg/kg;albendazole 800mg and ivermectin 400mcg/kg bi-annually

Search NIH Clinical Center for Filariasis

Genetic Tests for Filariasis

Anatomical Context for Filariasis

MalaCards organs/tissues related to Filariasis:

40
Testes, Breast, Skin, T Cells, Lung, Liver, Lymph Node

Publications for Filariasis

Articles related to Filariasis:

(showing 6392, show less)
# Title Authors PMID Year
1
Protective immunity in human filariasis: a role for parasite-specific IgA responses. 54 61
18588480 2008
2
Chitotriosidase deficiency is not associated with human hookworm infection in a Papua New Guinean population. 61 54
17765019 2007
3
IgE memory: persistence of antigen-specific IgE responses years after treatment of human filarial infections. 61 54
16630955 2006
4
Interleukin-10 (IL-10) counterregulates IL-4-dependent effector mechanisms in Murine Filariasis. 54 61
15501755 2004
5
Polymorphisms of innate immunity genes and susceptibility to lymphatic filariasis. 61 54
14551607 2003
6
A four year follow up study of filaria specific IgE response in individuals with hydrocele. 54 61
11247197 2000
7
IL-5 is essential for vaccine-induced protection and for resolution of primary infection in murine filariasis. 61 54
11138639 2000
8
Antigen-stimulated IL-4, IL-13 and IFN-gamma production by human T cells at a single-cell level. 61 54
9808184 1998
9
Differential decline in filaria-specific IgG1, IgG4, and IgE antibodies in Brugia malayi-infected patients after diethylcarbamazine chemotherapy. 61 54
7594718 1995
10
Differential antibody isotype reactivity to specific antigens in human lymphatic filariasis: gp15/400 preferentially induces immunoglobulin E (IgE), IgG4, and IgG2. 54 61
7558279 1995
11
Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. 61 54
8473742 1993
12
Cytokine regulation of antigen-driven immunoglobulin production in filarial parasite infections in humans. 54 61
2112154 1990
13
The immune response of inbred laboratory mice to Litomosoides sigmodontis: A route to discovery in myeloid cell biology. 61
32145033 2020
14
Microfilaria in urine cytology: Report of three cases with review of literature. 61
32259405 2020
15
Green synthesis of silver nanoparticles using Indian Belladonna extract and their potential antioxidant, anti-inflammatory, anticancer and larvicidal activities. 61
32300886 2020
16
Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis. 61
32479495 2020
17
Standardisation of lymphatic filariasis microfilaraemia prevalence estimates based on different diagnostic methods: a systematic review and meta-analysis. 61
32527335 2020
18
Post-Treatment Surveillance for Lymphatic Filariasis in Plateau and Nasarawa States, Nigeria: Results of Transmission Assessment Surveys. 61
32228796 2020
19
Nearly Complete Genome Sequence of Brugia malayi Strain FR3. 61
32527783 2020
20
The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Democratic Republic of the Congo. 61
32574160 2020
21
Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study. 61
32511226 2020
22
Pancytopenia: a rare cause for a common presentation. 61
32539585 2020
23
Design, expression, and evaluation of novel multiepitope chimeric antigen of Wuchereria bancrofti for the diagnosis of lymphatic filariasis - A structure-based strategy. 61
32222640 2020
24
When, Who, and How to Sample: Designing Practical Surveillance for 7 Neglected Tropical Diseases as We Approach Elimination. 61
32529261 2020
25
Design and Analysis of Elimination Surveys for Neglected Tropical Diseases. 61
31930383 2020
26
Designing antifilarial drug trials using clinical trial simulators. 61
32483209 2020
27
Massive microfilaremia in a dog subclinically infected with Acanthocheilonema dracunculoides. 61
32036036 2020
28
Immunolocalization of Disorganized Muscle Protein-1 in Different Life Stages of Human Lymphatic Filariid, Brugia malayi. 61
32500507 2020
29
Pediatric Allergic Diseases in the Indian Subcontinent -Epidemiology, Risk Factors and Current Challenges. 61
32521565 2020
30
Genetic and functional diversification of chemosensory pathway receptors in mosquito-borne filarial nematodes. 61
32511224 2020
31
The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs. 61
31343064 2020
32
Elimination or Resurgence: Modelling Lymphatic Filariasis After Reaching the 1% Microfilaremia Prevalence Threshold. 61
31853554 2020
33
An outbreak of acute skin and soft tissue infections including necrotizing fasciitis in Kalwala village, India, 2018: Public health implications for the lymphatic filariasis elimination program. 61
32562418 2020
34
Eliminating Lymphatic Filariasis: Is it Worth it? 61
31343066 2020
35
A systematic review of alternative surveillance approaches for lymphatic filariasis in low prevalence settings: Implications for post-validation settings. 61
32396575 2020
36
Review of MDA registers for Lymphatic Filariasis: Findings, and potential uses in addressing the endgame elimination challenges. 61
32407319 2020
37
Significant improvement in quality of life following surgery for hydrocoele caused by lymphatic filariasis in Malawi: A prospective cohort study. 61
32384094 2020
38
Prevalence and Correlates of Lymphatic Filariasis Infection and Its Morbidity Following Mass Ivermectin and Albendazole Administration in Mkinga District, North-Eastern Tanzania. 61
32455556 2020
39
The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: A case study. 61
32469860 2020
40
Factors Influencing the Sustainability of Neglected Tropical Disease Elimination Programs: A Multi-Case Study of the Kenya National Program for Elimination of Lymphatic Filariasis. 61
32124717 2020
41
Notes from the Field: Impact of a Mass Drug Administration Campaign Using a Novel Three-Drug Regimen on Lymphatic Filariasis Antigenemia - American Samoa, 2019. 61
32463808 2020
42
Space occupying lesion of brain: An unusual site for a common infection. 61
32365273 2020
43
Hospitalization for Chagas disease, dengue, filariasis, leishmaniasis, schistosomiasis, strongyloidiasis, and Taenia solium taeniasis/cysticercosis, Italy, 2011-2016. 61
32418191 2020
44
Biological effects of Avicennia marina (Forssk.) vierh. extracts on physiological, biochemical, and antimicrobial activities against three challenging mosquito vectors and microbial pathogens. 61
32072409 2020
45
Antibody response to Schistosoma haematobium and other helminth species in malaria-exposed populations from Burkina Faso. 61
32007449 2020
46
Embryo Microinjection Techniques for Efficient Site-Specific Mutagenesis in Culex quinquefasciatus. 61
32510506 2020
47
Who Bites Me? A Tentative Discriminative Key to Diagnose Hematophagous Ectoparasites Biting Using Clinical Manifestations. 61
32429276 2020
48
Fecundity of adult female worms were affected when Brugia malayi infected Mongolian gerbils were immunized with a multivalent vaccine (rBmHAXT) against human lymphatic filarial parasite. 61
32437645 2020
49
Inhibition of Asaia in Adult Mosquitoes Causes Male-Specific Mortality and Diverse Transcriptome Changes. 61
32429180 2020
50
Essential oils from three Algerian medicinal plants (Artemisia campestris, Pulicaria arabica, and Saccocalyx satureioides) as new botanical insecticides? 61
32372353 2020
51
Ivermectin: repurposing a multipurpose drug for Venezuela's humanitarian crisis. 61
32479893 2020
52
Detection of Canine Vector-Borne Filariasis and Their Wolbachia Endosymbionts in French Guiana. 61
32455576 2020
53
Development of a molecular xenomonitoring protocol to assess filariasis transmission. 61
32464220 2020
54
Acute Lymphatic Filariasis Infection in United States Armed Forces Personnel Deployed to the Pacific Area of Operations during World War II Provides Important Lessons for Today. 61
32316470 2020
55
Mapping lymphatic filariasis in Loa loa endemic health districts naïve for ivermectin mass administration and situated in the forested zone of Cameroon. 61
32299374 2020
56
Elucidating the possible mechanism of action of some pathogen box compounds against Leishmania donovani. 61
32275665 2020
57
Investigating barriers and challenges to the integrated management of neglected tropical skin diseases in an endemic setting in Nigeria. 61
32352967 2020
58
Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. 61
31948767 2020
59
Focus of Ongoing Onchocerciasis Transmission Close to Bangui, Central African Republic. 61
32365847 2020
60
Macrofilaricides: An Unmet Medical Need for Filarial Diseases. 61
32091199 2020
61
Filarial worms: a systematic review and meta-analysis of diversity in animals from Iran with emphasis on human cases. 61
32249728 2020
62
Filarial infections in California sea lions vary spatially within the Gulf of California, Mexico. 61
32166425 2020
63
In vivo imaging of transgenic Brugia malayi. 61
32243453 2020
64
Effect of Brugia pahangi co-infection with Plasmodium berghei ANKA in gerbils (Meriones unguiculatus). 61
32179986 2020
65
Exploring essential oils of Slovak medicinal plants for insecticidal activity: The case of Thymus alternans and Teucrium montanum subsp. jailae. 61
32074491 2020
66
Safety of high-dose ivermectin: a systematic review and meta-analysis. 61
31960060 2020
67
Loa loa filariasis in a tropical savanna area: report of one case in Ouagadougou. 61
31975376 2020
68
Characterization of aortic and brachiocephalic filariasis by Filarioidea sp (Nematoda:Spirurida:Filarioidea) in Mexican ramphastids. 61
32211290 2020
69
Demographic, socioeconomic and disease knowledge factors, but not population mobility, associated with lymphatic filariasis infection in adult workers in American Samoa in 2014. 61
32164780 2020
70
The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. 61
32114985 2020
71
The Interruption of Transmission of Human Onchocerciasis by an Annual Mass Drug Administration Program in Plateau and Nasarawa States, Nigeria. 61
32043442 2020
72
The impact of leprosy, podoconiosis and lymphatic filariasis on family quality of life: A qualitative study in Northwest Ethiopia. 61
32155158 2020
73
Current status of neglected tropical diseases (NTDs) in the Philippines. 61
31786109 2020
74
Melorheostosis of upper limb: A report of four rare cases. 61
32099304 2020
75
Quantifying the socio-economic impact of leg lymphoedema on patient caregivers in a lymphatic filariasis and podoconiosis co-endemic district of Ethiopia. 61
32126081 2020
76
The design and development of a multicentric protocol to investigate the impact of adjunctive doxycycline on the management of peripheral lymphoedema caused by lymphatic filariasis and podoconiosis. 61
32228663 2020
77
Economic benefits and costs of surgery for filarial hydrocele in Malawi. 61
32210436 2020
78
Rodents as Hosts of Pathogens and Related Zoonotic Disease Risk. 61
32164206 2020
79
The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial. 61
32176703 2020
80
Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé foci, Mali. 61
32206773 2020
81
Novel anti-Wolbachia drugs, a new approach in the treatment and prevention of veterinary filariasis? 61
32126342 2020
82
The Burden of Bancroftian Filariasis in Nigeria: A Review. 61
32165820 2020
83
Imported bancroftian filariasis discovered in a patient infected with Plasmodium falciparum: First case of concomitant parasitism in the Al-Buraimi Governorate, Oman. 61
32318255 2020
84
The Genome of Setaria digitata: A Cattle Nematode Closely Related to Human Filarial Parasites. 61
32022853 2020
85
Schistosomiasis, strongyloidiasis and Chagas disease: the leading imported neglected tropical diseases in Italy. 61
31840757 2020
86
Urological infections in the developing world: an increasing problem in developed countries. 61
32108257 2020
87
The Elimination of Neglected Tropical Diseases: A Case Study Exemplifying How Foreign Assistance Funding Can Be Catalytic in Reducing the Burden of Major Global Health Conditions. 61
31402376 2020
88
Macrofilaricidal Benzimidazole-Benzoxaborole Hybrids as an Approach to the Treatment of River Blindness: Part 1. Amide Linked Analogs. 61
31876154 2020
89
Activation of mosquito immunity blocks the development of transmission-stage filarial nematodes. 61
32015105 2020
90
Ivermectin concentration in breastmilk of a woman with Strongyloides stercoralis and human T-lymphotropic virus-I co-infection. 61
31678122 2020
91
Advances in Vaccine Development for Human Lymphatic Filariasis. 61
31864894 2020
92
The rise or fall of neglected tropical diseases in East Asia Pacific. 61
31550453 2020
93
A Study On Serological Reactivity Profile Of Different Antigen Preparations With Bancroftian Filariasis Human Infection Sera. 61
32096736 2020
94
Low transmission of Wuchereria bancrofti in cross-border districts of Côte d'Ivoire: A great step towards lymphatic filariasis elimination in West Africa. 61
32282840 2020
95
Molecular xenomonitoring as a post-MDA surveillance tool for global programme to eliminate lymphatic filariasis: Field validation in an evaluation unit in India. 61
31978060 2020
96
Non-compliance to Mass Drug Administration Associated with the Low Perception of the Community Members About their Susceptibility to Lymphatic Filariasis in Ankobra, Ghana. 61
30727921 2020
97
A review on the druggability of a thiol-based enzymatic antioxidant thioredoxin reductase for treating filariasis and other parasitic infections. 61
31521661 2020
98
Frequency and Clinical Significance of Localized Adverse Events following Mass Drug Administration for Lymphatic Filariasis in an Endemic Area in South India. 61
31769393 2020
99
Brugia malayi galectin 2 is a tandem-repeat type galectin capable of binding mammalian polysaccharides. 61
31738955 2020
100
In vivo efficacy of the boron-pleuromutilin AN11251 against Wolbachia of the rodent filarial nematode Litomosoides sigmodontis. 61
31986143 2020
101
Incidental detection of microfilaria in cyst fluid of Mucinous cystadenocarcinoma of ovary: A rare case report. 61
32416487 2020
102
Isolated Epitrochlear Filarial Lymphadenopathy: Cytomorphological Diagnosis of an Unusual Presentation. 61
29630086 2020
103
Testing a method of sampling for entomological determination of transmission of Wuchereria bancrofti to inform lymphatic filariasis treatment strategy in urban settings. 61